Foresite Capital
Foresite Capital is a multi-stage healthcare and life sciences investment firm dedicated to addressing significant unmet needs by funding promising businesses at all stages of their life cycles. The firm employs a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare. Foresite Capital focuses on breakthrough opportunities at the intersection of technology and biotech, systematically identifying key undercurrents driving change.
Foresite Capital
900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939
Portfolio
10x Genomics is a leader in single-cell and spatial genomics, providing solutions that enable researchers to understand complex biological systems at a resolution and scale that matches the complexity of biology.
#Genomics
Kinnate Biopharma focuses on developing targeted therapies for genomically defined cancers. The company went public on NASDAQ under the ticker KNTE.
#Biopharmaceuticals
ImmPACT Bio is developing next-generation cancer therapies based on transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted other treatment options.
#Biotechnology
Seaport Therapeutics is focused on developing prodrugs for Major Depressive Disorder (MDD) and anxiety, utilizing their Glyph platform to enhance drug delivery by bypassing the liver.
#Neuropsychiatric Disorders
Affinivax was acquired by GSK to advance their vaccines that combat novel and resistant infectious diseases. Their MAPS platform offers a new approach to vaccines by combining polysaccharides and proteins.
#Vaccines
XinThera was acquired by Gilead Sciences. Founded in 2021 by serial entrepreneurs, XinThera focuses on innovative solutions in biotechnology.
#Biotechnology
Key People
Managing Director